Skip to main content
Fig. 1 | Microbial Cell Factories

Fig. 1

From: Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19

Fig. 1

Scheme of Spike (S) protein architecture of the SARS-CoV-2 (A): NTD N-terminal domain, RBD receptor-binding domain (330–525 WA1/2020), RBD-P receptor-binding domain fused to 40AV peptide, RBM receptor binding motif, SD1 subdomain 1, SD2 subdomain 2, S1/S2 protease cleavage site, S2' protease cleavage site, FP fusion peptide, HR1 heptad repeat 1, CH central helix, HR2 heptad repeat 2, TM transmembrane domain. Representative scheme of the peptide fused RBD and peptide free RBD (B)

Back to article page